53 results
8-K
EX-3.2
JNCE
Jounce Therapeutics Inc
4 May 23
Termination of a Material Definitive Agreement
7:22am
of the Corporation, shall be responsible for
corporate policy and strategy, and shall report directly to the Board of Directors. Unless otherwise provided
SC TO-T/A
EX-99
JNCE
Jounce Therapeutics Inc
25 Apr 23
Third party tender offer statement (amended)
6:07am
. Jounce’s strategy is to use a biomarker-driven approach from discovery through clinical development. Jounce has developed a suite of integrated
SC 14D9
JNCE
Jounce Therapeutics Inc
6 Apr 23
Tender offer solicitation
2:51pm
of such risks and uncertainties on the Company’s standalone strategy and the trading price of the Shares;
Best Offer. The Jounce Board’s belief that (i
SC TO-T
EX-99
Concentra Merger Sub, Inc.
6 Apr 23
Third party tender offer statement
2:11pm
. Jounce’s strategy is to use a biomarker-driven approach from discovery through clinical development. Jounce has developed a suite of integrated
8-K
EX-99.1
zi09gt0xz5fe9mri
30 Aug 22
Regulation FD Disclosure
8:07am
8-K
EX-99.1
b3v xwyheb5ohqu8a9pm
4 Aug 22
Jounce Therapeutics Reports Second Quarter 2022 Financial Results
7:13am
8-K
EX-99.1
n26kxq1obeh3
7 Mar 22
Regulation FD Disclosure
7:06am
8-K
EX-99.1
mhomc 3ey78jrksev02j
10 Jan 22
Results of Operations and Financial Condition
7:31am
424B5
sjqqb7 2v3
4 Nov 21
Prospectus supplement for primary offering
4:17pm
8-K
EX-99.1
tvk nftxyzby
4 Nov 21
Jounce Therapeutics Reports Third Quarter 2021 Financial Results
7:12am
8-K
EX-99.1
p9cfmxt0aoyv1xu ed
5 Aug 21
Jounce Therapeutics Reports Second Quarter 2021 Financial Results
6:37am